United States Biotechnology & Medical Research

Adicet Bio Inc (ACET)

Track

The most recent insider trading activity occurred in April 2026, with significant proposed sales and sales transactions by entities associated with OrbiMed. Prior to this, in February 2026, Ra Capital Management engaged in substantial buying activity. Earlier transactions in October 2025 also show buying from OrbiMed Advisors LLC.
Ticker: ACET Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Adicet Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
OrbiMed Genesis Master Fund, L.P.
Shareholder
1 sale — total 514,168 USD
Proposed sale 9 Apr 2026
Value US$1,547,564.80 | Price 434.53 | Shares 47,831
Sale 8 Apr 2026
Value US$4,118,315.80 | Price 179.07 | Shares 69,918
Sale 8 Apr 2026
Value US$4,759,169.64 | Price 26.59 | Shares 7,692
Proposed sale 8 Apr 2026
Value US$264,724.80 | Price 6.55 | Shares 40,416
Sale 7 Apr 2026
Value US$15,312.00 | Price 6.38 | Shares 2,400
Sale 7 Apr 2026
Value US$191,453.07 | Price 6.53 | Shares 29,319
Proposed sale 7 Apr 2026
Value US$413,076.06 | Price 6.43 | Shares 64,242
Buy 20 Feb 2026
Value US$543,439.77 | Price 7.27 | Shares 74,751
Buy 19 Feb 2026
Value US$535,472.28 | Price 7.21 | Shares 74,268
Buy 18 Feb 2026
Value US$525,022.08 | Price 7.04 | Shares 74,577
Buy 8 Oct 2025
Value US$3,500,000.00 | Price 1.00 | Shares 3,500,000
Buy 8 Oct 2025
Value US$1,500,000.00 | Price 1.00 | Shares 1,500,000
Sale 5 Jun 2024
Value US$8,437.00 | Price 1.43 | Shares 5,900
Proposed sale 5 Jun 2024
Value US$8,437.00 | Price 1.43 | Shares 5,900
Buy 25 Jan 2024
Value US$2,500,080.00 | Price 2.40 | Shares 1,041,700
Buy 25 Jan 2024
Value US$581,280.00 | Price 2.40 | Shares 242,200
Buy 25 Jan 2024
Value US$4,418,640.00 | Price 2.40 | Shares 1,841,100
Buy 25 Jan 2024
Value US$2,500,080.00 | Price 2.40 | Shares 1,041,700
Buy 25 Jan 2024
Value US$581,280.00 | Price 2.40 | Shares 242,200
Buy 25 Jan 2024
Value US$4,418,640.00 | Price 2.40 | Shares 1,841,100
Buy 2 Oct 2023
Value US$7,339.75 | Price 1.33 | Shares 5,500
Sale 29 Sep 2023
Value US$7,480.55 | Price 1.36 | Shares 5,500
Proposed sale 29 Sep 2023
Value US$7,480.55 | Price 1.36 | Shares 5,500
Buy 28 Sep 2023
Value US$7,810.00 | Price 1.42 | Shares 5,500
Sale 28 Sep 2023
Value US$7,810.00 | Price 1.42 | Shares 5,500
Buy 27 Jun 2023
Value US$121,220.00 | Price 2.09 | Shares 58,000
Buy 27 Jun 2023
Value US$923,780.00 | Price 2.09 | Shares 442,000
Buy 27 Jun 2023
Value US$522,500.00 | Price 2.09 | Shares 250,000
Buy 27 Jun 2023
Value US$261,250.00 | Price 2.09 | Shares 125,000
Buy 27 Jun 2023
Value US$121,220.00 | Price 2.09 | Shares 58,000
Buy 27 Jun 2023
Value US$923,780.00 | Price 2.09 | Shares 442,000
Buy 27 Jun 2023
Value US$522,500.00 | Price 2.09 | Shares 250,000
Buy 27 Jun 2023
Value US$261,250.00 | Price 2.09 | Shares 125,000
Planned sale 15 Feb 2023
Value US$34,326.60 | Price 7.57 | Shares 4,533
Planned sale 10 Feb 2023
Value US$83,476.42 | Price 7.98 | Shares 10,467
Planned sale 10 Nov 2022
Value US$601,920.00 | Price 20.06 | Shares 30,000
Planned sale 10 Nov 2022
Value US$209,321.79 | Price 21.03 | Shares 9,955
Planned sale 10 Nov 2022
Value US$146,307.00 | Price 21.00 | Shares 6,967
Planned sale 7 Nov 2022
Value US$571,488.00 | Price 19.05 | Shares 30,000
Planned sale 3 Nov 2022
Value US$447,718.33 | Price 18.04 | Shares 24,813
Planned sale 2 Nov 2022
Value US$9,000.00 | Price 18.00 | Shares 500
Planned sale 19 Oct 2022
Value US$131,250.09 | Price 16.27 | Shares 8,067
Planned sale 12 Oct 2022
Value US$25,348.40 | Price 15.40 | Shares 1,646
Planned sale 14 Sep 2022
Value US$17,136.00 | Price 18.00 | Shares 952
Planned sale 13 Sep 2022
Value US$60,713.40 | Price 18.01 | Shares 3,371
Planned sale 12 Sep 2022
Value US$3,600.00 | Price 18.00 | Shares 200
Planned sale 12 Sep 2022
Value US$1,119,307.14 | Price 16.77 | Shares 66,747
Planned sale 9 Sep 2022
Value US$133,601.18 | Price 16.51 | Shares 8,094
Planned sale 3 Aug 2022
Value US$125,424.00 | Price 18.00 | Shares 6,968
Planned sale 1 Aug 2022
Value US$115,947.52 | Price 16.64 | Shares 6,968
Planned sale 5 Jul 2022
Value US$19,763.50 | Price 14.50 | Shares 1,363
Planned sale 4 Apr 2022
Value US$37,275.00 | Price 21.00 | Shares 1,775
Planned sale 4 Apr 2022
Value US$3,528.00 | Price 21.00 | Shares 168
Planned sale 4 Apr 2022
Value US$126,756.00 | Price 21.00 | Shares 6,036
Planned sale 1 Apr 2022
Value US$160,041.00 | Price 21.00 | Shares 7,621
Planned sale 9 Mar 2022
Value US$28,000.00 | Price 14.00 | Shares 2,000
Planned sale 9 Mar 2022
Value US$28,000.00 | Price 14.00 | Shares 2,000
Planned sale 16 Feb 2022
Value US$29,663.80 | Price 14.83 | Shares 2,000
Planned sale 16 Feb 2022
Value US$29,663.80 | Price 14.83 | Shares 2,000
Planned sale 9 Feb 2022
Value US$56,121.20 | Price 14.03 | Shares 4,000
Planned sale 9 Feb 2022
Value US$56,117.60 | Price 14.03 | Shares 4,000
Planned sale 5 Jan 2022
Value US$33,799.00 | Price 16.90 | Shares 2,000
Planned sale 5 Jan 2022
Value US$33,864.00 | Price 16.93 | Shares 2,000
Planned sale 3 Jan 2022
Value US$108,130.80 | Price 18.02 | Shares 6,000
Planned sale 3 Jan 2022
Value US$108,124.80 | Price 18.02 | Shares 6,000
Buy 8 Dec 2021
Value US$7,000,000.00 | Price 14.00 | Shares 500,000
Planned sale 15 Jun 2021
Value US$21,453.95 | Price 11.16 | Shares 1,923
Planned sale 15 Jun 2021
Value US$21,465.11 | Price 11.16 | Shares 1,924
Planned sale 3 Jun 2021
Value US$108,278.91 | Price 12.06 | Shares 8,982
Planned sale 3 Jun 2021
Value US$90,220.37 | Price 12.06 | Shares 7,484
Planned sale 20 May 2021
Value US$12,805.20 | Price 14.23 | Shares 900
Planned sale 20 May 2021
Value US$12,692.36 | Price 14.23 | Shares 892
Planned sale 19 May 2021
Value US$10,062.40 | Price 13.73 | Shares 733
Planned sale 19 May 2021
Value US$110,727.98 | Price 13.42 | Shares 8,249
Planned sale 19 May 2021
Value US$8,401.35 | Price 13.73 | Shares 612
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-09 2026-04-09 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
47,831
434.53
US$1,547,565 		47,831 434.53 US$1,547,565
2026-04-09 2026-04-08 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
69,918 -16.9%
179.07
US$4,118,316 		69,918 -16.9% 179.07 US$4,118,316
2026-04-09 2026-04-08 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
7,692 -7.1%
26.59
US$4,759,170 		7,692 -7.1% 26.59 US$4,759,170
2026-04-08 2026-04-08 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
40,416
6.55
US$264,725 		40,416 6.55 US$264,725
2026-04-09 2026-04-07 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
2,400 -6.9%
6.38
US$15,312 		2,400 -6.9% 6.38 US$15,312
2026-04-09 2026-04-07 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
29,319 -45.6%
6.53
US$191,453 		29,319 -45.6% 6.53 US$191,453
2026-04-07 2026-04-07 PrS Proposed sale
3.9
OrbiMed Israel Partners Limited Partnership

Shareholder
64,242
6.43
US$413,076 		64,242 6.43 US$413,076
2026-04-13 2026-02-20 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
74,751 +6.7%
7.27
US$543,440 		74,751 +6.7% 7.27 US$543,440
2026-04-13 2026-02-19 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
74,268 +7.2%
7.21
US$535,472 		74,268 +7.2% 7.21 US$535,472
2026-04-13 2026-02-18 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
74,577 +7.8%
7.04
US$525,022 		74,577 +7.8% 7.04 US$525,022
2025-10-10 2025-10-08 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
3,500,000 +353.4%
1.00
US$3,500,000 		3,500,000 +353.4% 1.00 US$3,500,000
2025-10-10 2025-10-08 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
1,500,000 +19.9%
1.00
US$1,500,000 		1,500,000 +19.9% 1.00 US$1,500,000
2024-06-07 2024-06-05 S Sale
3.9
Kauffman Michael
Non-Executive Director
5,900 -50.0%
1.43
US$8,437 		5,900 -50.0% 1.43 US$8,437
2024-06-05 2024-06-05 PrS Proposed sale
3.9
Kauffman Michael

Director

Non-Executive Director
5,900
1.43
US$8,437 		5,900 1.43 US$8,437
2024-01-26 2024-01-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,041,700 +486.1%
2.40
US$2,500,080 		1,041,700 +486.1% 2.40 US$2,500,080
2024-01-26 2024-01-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
242,200 +32.4%
2.40
US$581,280 		242,200 +32.4% 2.40 US$581,280
2024-01-26 2024-01-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,841,100 +32.4%
2.40
US$4,418,640 		1,841,100 +32.4% 2.40 US$4,418,640
2024-01-26 2024-01-25 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
1,041,700 +486.1%
2.40
US$2,500,080 		1,041,700 +486.1% 2.40 US$2,500,080
2024-01-26 2024-01-25 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
242,200 +32.4%
2.40
US$581,280 		242,200 +32.4% 2.40 US$581,280
2024-01-26 2024-01-25 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
1,841,100 +32.4%
2.40
US$4,418,640 		1,841,100 +32.4% 2.40 US$4,418,640
2023-10-02 2023-10-02 B Purchase
1.7
Schor Chen

President & CEO

Executive Director
5,500 +14.5%
1.33
US$7,340 		5,500 +14.5% 1.33 US$7,340
2023-10-02 2023-09-29 S Sale
1.7
Schor Chen

President & CEO

Executive Director
5,500 -3.0%
1.36
US$7,481 		5,500 -3.0% 1.36 US$7,481
2023-09-29 2023-09-29 PrS Proposed sale
1.7
CHEN SCHOR

Officer; Director

Executive Director
5,500
1.36
US$7,481 		5,500 1.36 US$7,481
2023-10-02 2023-09-28 B Purchase
1.7
Schor Chen

President & CEO

Executive Director
5,500 +3.1%
1.42
US$7,810 		5,500 +3.1% 1.42 US$7,810
2023-10-02 2023-09-28 S Sale
1.7
Schor Chen

President & CEO

Executive Director
5,500 -12.7%
1.42
US$7,810 		5,500 -12.7% 1.42 US$7,810
2023-06-29 2023-06-27 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
58,000 +8.4%
2.09
US$121,220 		58,000 +8.4% 2.09 US$121,220
2023-06-29 2023-06-27 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
442,000 +8.4%
2.09
US$923,780 		442,000 +8.4% 2.09 US$923,780
2023-06-29 2023-06-27 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
250,000 +63.0%
2.09
US$522,500 		250,000 +63.0% 2.09 US$522,500
2023-06-29 2023-06-27 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
125,000 +13.8%
2.09
US$261,250 		125,000 +13.8% 2.09 US$261,250
2023-06-29 2023-06-27 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
58,000 +8.4%
2.09
US$121,220 		58,000 +8.4% 2.09 US$121,220
2023-06-29 2023-06-27 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
442,000 +8.4%
2.09
US$923,780 		442,000 +8.4% 2.09 US$923,780
2023-06-29 2023-06-27 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
250,000 +63.0%
2.09
US$522,500 		250,000 +63.0% 2.09 US$522,500
2023-06-29 2023-06-27 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
125,000 +13.8%
2.09
US$261,250 		125,000 +13.8% 2.09 US$261,250
2023-02-17 2023-02-15 PlS Planned sale
Healey Don

Chief Technology Officer

Officer
4,533 -6.4%
7.57
US$34,327 		4,533 -6.4% 7.57 US$34,327
2023-02-14 2023-02-10 PlS Planned sale
Healey Don

Chief Technology Officer

Officer
10,467 -12.8%
7.98
US$83,476 		10,467 -12.8% 7.98 US$83,476
2022-11-15 2022-11-10 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
30,000 -36.0%
20.06
US$601,920 		30,000 -36.0% 20.06 US$601,920
2022-11-15 2022-11-10 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
9,955 -9.8%
21.03
US$209,322 		9,955 -9.8% 21.03 US$209,322
2022-11-15 2022-11-10 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
6,967 -19.8%
21.00
US$146,307 		6,967 -19.8% 21.00 US$146,307
2022-11-09 2022-11-07 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
30,000 -26.4%
19.05
US$571,488 		30,000 -26.4% 19.05 US$571,488
2022-11-04 2022-11-03 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
24,813 -17.9%
18.04
US$447,718 		24,813 -17.9% 18.04 US$447,718
2022-11-04 2022-11-02 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
500 -0.4%
18.00
US$9,000 		500 -0.4% 18.00 US$9,000
2022-10-21 2022-10-19 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
8,067 -18.7%
16.27
US$131,250 		8,067 -18.7% 16.27 US$131,250
2022-10-14 2022-10-12 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
1,646 -3.1%
15.40
US$25,348 		1,646 -3.1% 15.40 US$25,348
2022-09-16 2022-09-14 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
952 -0.7%
18.00
US$17,136 		952 -0.7% 18.00 US$17,136
2022-09-13 2022-09-13 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
3,371 -2.4%
18.01
US$60,713 		3,371 -2.4% 18.01 US$60,713
2022-09-13 2022-09-12 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
200 -0.1%
18.00
US$3,600 		200 -0.1% 18.00 US$3,600
2022-09-13 2022-09-12 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
66,747 -100.0%
16.77
US$1,119,307 		66,747 -100.0% 16.77 US$1,119,307
2022-09-13 2022-09-09 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
8,094 -10.8%
16.51
US$133,601 		8,094 -10.8% 16.51 US$133,601
2022-08-05 2022-08-03 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
6,968 -15.2%
18.00
US$125,424 		6,968 -15.2% 18.00 US$125,424
2022-08-03 2022-08-01 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
6,968 -13.2%
16.64
US$115,948 		6,968 -13.2% 16.64 US$115,948
2022-07-07 2022-07-05 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
1,363 -2.5%
14.50
US$19,764 		1,363 -2.5% 14.50 US$19,764
2022-04-05 2022-04-04 PlS Planned sale
Galimi Francesco

SVP & Chief Medical Officer

Officer
1,775 -2.9%
21.00
US$37,275 		1,775 -2.9% 21.00 US$37,275
2022-04-05 2022-04-04 PlS Planned sale
Galimi Francesco

SVP & Chief Medical Officer

Officer
168 -0.3%
21.00
US$3,528 		168 -0.3% 21.00 US$3,528
2022-04-05 2022-04-04 PlS Planned sale
Galimi Francesco

SVP & Chief Medical Officer

Officer
6,036 -9.2%
21.00
US$126,756 		6,036 -9.2% 21.00 US$126,756
2022-04-05 2022-04-01 PlS Planned sale
Galimi Francesco

SVP & Chief Medical Officer

Officer
7,621 -11.3%
21.00
US$160,041 		7,621 -11.3% 21.00 US$160,041
2022-03-11 2022-03-09 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.6%
14.00
US$28,000 		2,000 -0.6% 14.00 US$28,000
2022-03-11 2022-03-09 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.6%
14.00
US$28,000 		2,000 -0.6% 14.00 US$28,000
2022-02-17 2022-02-16 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.6%
14.83
US$29,664 		2,000 -0.6% 14.83 US$29,664
2022-02-17 2022-02-16 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.6%
14.83
US$29,664 		2,000 -0.6% 14.83 US$29,664
2022-02-14 2022-02-09 PlS Planned sale
Jakobovits Aya
Non-Executive Director
4,000 -1.1%
14.03
US$56,121 		4,000 -1.1% 14.03 US$56,121
2022-02-14 2022-02-09 PlS Planned sale
Jakobovits Aya
Non-Executive Director
4,000 -1.1%
14.03
US$56,118 		4,000 -1.1% 14.03 US$56,118
2022-02-14 2022-01-05 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.5%
16.90
US$33,799 		2,000 -0.5% 16.90 US$33,799
2022-02-14 2022-01-05 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.5%
16.93
US$33,864 		2,000 -0.5% 16.93 US$33,864
2022-02-14 2022-01-03 PlS Planned sale
Jakobovits Aya
Non-Executive Director
6,000 -1.6%
18.02
US$108,131 		6,000 -1.6% 18.02 US$108,131
2022-02-14 2022-01-03 PlS Planned sale
Jakobovits Aya
Non-Executive Director
6,000 -1.6%
18.02
US$108,125 		6,000 -1.6% 18.02 US$108,125
2021-12-10 2021-12-08 B Purchase
3.4
Sinclair Andrew
Non-Executive Director
500,000 +30.5%
14.00
US$7,000,000 		500,000 +30.5% 14.00 US$7,000,000
2021-06-17 2021-06-15 PlS Planned sale
Jakobovits Aya
Non-Executive Director
1,923 -0.9%
11.16
US$21,454 		1,923 -0.9% 11.16 US$21,454
2021-06-17 2021-06-15 PlS Planned sale
Jakobovits Aya
Non-Executive Director
1,924 -0.9%
11.16
US$21,465 		1,924 -0.9% 11.16 US$21,465
2021-06-07 2021-06-03 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
8,982 -8.3%
12.06
US$108,279 		8,982 -8.3% 12.06 US$108,279
2021-06-07 2021-06-03 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
7,484 -8.3%
12.06
US$90,220 		7,484 -8.3% 12.06 US$90,220
2021-05-20 2021-05-20 PlS Planned sale
Jakobovits Aya
Non-Executive Director
900 -0.4%
14.23
US$12,805 		900 -0.4% 14.23 US$12,805
2021-05-20 2021-05-20 PlS Planned sale
Jakobovits Aya
Non-Executive Director
892 -0.4%
14.23
US$12,692 		892 -0.4% 14.23 US$12,692
2021-05-21 2021-05-19 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
733 -0.7%
13.73
US$10,062 		733 -0.7% 13.73 US$10,062
2021-05-21 2021-05-19 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
8,249 -7.1%
13.42
US$110,728 		8,249 -7.1% 13.42 US$110,728
2021-05-21 2021-05-19 PlS Planned sale
1.7
Schor Chen

President & CEO

Executive Director
612 -0.7%
13.73
US$8,401 		612 -0.7% 13.73 US$8,401
Explore more

More insider trading research around Adicet Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America